Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Migraine Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The migraine drugs market size has grown strongly in recent years, from $5 billion in 2023 to $5.38 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be attributed to various factors, including advancements in drug formulations, heightened awareness and diagnosis of migraines, the impact of stress and lifestyle factors on migraine prevalence, the expansion of generic drugs in the market, and the emergence of CGRP (calcitonin gene-related peptide) inhibitors as a notable treatment option.
The migraine drugs market size is expected to see continued strong growth in the next few years, reaching $6.84 billion in 2028 at a CAGR of 6.2%. The anticipated growth in the forecast period can be attributed to several factors, including the adoption of personalized medicine approaches in migraine treatment, the increasing use of telemedicine and remote consultations for healthcare delivery, the influence of healthcare policy and insurance coverage on migraine care, the rising global burden of migraines, and the exploration of combination therapies.
Key trends expected in the forecast period include the development of targeted therapies, the continued use of telemedicine and remote consultations, a shift towards patient-centric approaches in migraine management, the emergence of digital therapeutics, the integration of biosimilars in migraine treatment, and an emphasis on clinical research and trials in this field.
The anticipated growth of the migraine drugs market is expected to be propelled by the increasing female population. The female population, encompassing females across all age groups in each country or region during a specific period, plays a crucial role in driving the demand for migraine medications. The prevalence of migraines is notably higher in the female population compared to males, influenced by a combination of genetic, hormonal, and environmental factors. As of 2022, according to the World Population Prospects 2022 released by the United Nations, the global female population is estimated at 4.0 billion, constituting 49.75% of the world population. Projections suggest that females will outnumber males by the year 2049. Consequently, the expanding female population serves as a key driver behind the growth of the migraine drugs market.
The increase in the prevalence of migraines is expected to further contribute to the growth of the migraine drug market in the coming years. Migraine headaches, characterized by recurring episodes of pulsing and pounding pain on one side of the brain, have become more prevalent, leading to a rising demand for effective migraine medications. This surge in prevalence fuels innovation and sales growth as pharmaceutical companies develop and provide therapies to address the needs of an expanding patient population. For instance, as reported in March 2023 by the Migraine Australia 2022-23 Pre-Budget Submissions, a document released by the Australian Treasury, Australia has one of the highest migraine rates globally (28%), affecting one in every four people. This prevalence surpasses that of type 2 diabetes, epilepsy, and asthma combined. Therefore, the increasing prevalence of migraines stands as a significant driver for the growth of the migraine drug market.
The anticipated growth of the migraine drug market is expected to face constraints due to the high cost associated with migraine treatment. The elevated expenses related to migraine therapy may create barriers to patients' access to effective migraine drugs, potentially hindering the overall growth of the migraine drug market. Affordability issues could result in restricted access to crucial medications, thereby impeding drug sales. For example, as reported in August 2022 by the Journal of Headache and Pain published in BioMed Central, a UK-based open-access publishing platform, the average price per prescription for migraine drugs had risen from $200 to $300. Consequently, the high cost of migraine treatment stands as a restraint on the growth of the migraine drug market.
Major companies operating in the migraine drugs market are concentrating on the development of innovative products to enhance patient care and gain a competitive advantage. One such example is Zavzpret, a nasal spray medication designed for the acute treatment of migraines with or without aura in adults. For example, in March 2023, Pfizer, a US-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Zavzpret. It is the first and only approved zavegepant (CGRP receptor antagonist) nasal spray for the acute treatment of migraine. Targeting the calcitonin gene-related peptide (CGRP), Zavzpret offers a new treatment option, particularly for individuals experiencing migraines with nausea and vomiting, as well as for those unable to use triptans due to cardiovascular risks.
The migraine drugs market consists of sales of analgesics, ergotamines, sumatriptan, and rizatriptan. The primary classes of migraine drugs include triptans, beta-blockers, angiotensin blockers, tricyclics, and anticonvulsants. Triptans, for example, work by altering blood circulation in the brain and modulating how the brain processes pain signals. These drugs can be administered through various routes, such as oral or injectable, and are utilized by diverse end-users, including hospitals and clinics, retail pharmacies, online pharmacies, and others.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Report Scope
Markets Covered:
- By Drug Class: Triptans; Betablockers; Angiotensin Blockers; Tricyclics; Anticonvulsants
- By Route of Administration: Oral; Injectable; Other Routes
- By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy; Other End Users
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value (USD) in 2024 | $5.38 Billion |
| Forecasted Market Value (USD) by 2028 | $6.84 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
Companies Profiled:
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Bayer
- Merck & Co. Inc.
- AbbVie Inc.
- AbbVie Inc.
- Sanofi SA
- Novartis AG
- AstraZeneca
- Abbott Laboratories
- GlaxoSmithKline plc.
- Eli Lilly and Company
- Amgen Inc.
- Otsuka Holdings Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
- Eisai Co. Ltd.
- Dr Reddys Laboratories Ltd.
- H. Lundbeck
- Amneal Pharmaceuticals Inc.
- Endo Pharmaceuticals Inc.
- Neurelis Inc.
- Alder Biopharmaceuticals
- eNeura Inc.
- Winston Pharmaceuticals Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/mm2y41
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
